

# Appendix 3B

## New issue announcement, application for quotation of additional securities and agreement

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

Elixir Petroleum Limited

ABN

51 108 230 995

We (the entity) give ASX the following information.

### Part 1 - All issues

*You must complete the relevant sections (attach sheets if there is not enough space).*

1	+Class of +securities issued or to be issued	<div> i) Ordinary Shares  ii) Options  iii) Ordinary Shares  iv) Options  v) Options  vi) Options  vii) Options  viii) Performance Rights </div>
2	Number of +securities issued or to be issued (if known) or maximum number which may be issued	<div> i) 160,000,000  ii) 80,000,000  iii) 440,000,000  iv) 220,000,000  v) 20,000,000  vi) 6,000,000  vii) 6,000,000  viii) 30,000,000 </div>

<p>3 Principal terms of the <sup>+</sup>securities (e.g. if options, exercise price and expiry date; if partly paid <sup>+</sup>securities, the amount outstanding and due dates for payment; if <sup>+</sup>convertible securities, the conversion price and dates for conversion)</p>	<table border="1"> <tr><td>i)</td><td>Fully paid ordinary Shares</td></tr> <tr><td>ii)</td><td>Options exercisable at \$0.015 on or before 30 September 2016</td></tr> <tr><td>iii)</td><td>Fully paid ordinary Shares</td></tr> <tr><td>iv)</td><td>Options exercisable at \$0.015 on or before 30 September 2016</td></tr> <tr><td>v)</td><td>Options exercisable at \$0.015 on or before 30 September 2016</td></tr> <tr><td>vi)</td><td>Options exercisable at \$0.015 (or such greater price as determined by the Company at its discretion) on or before 15 October 2016. The Options will vest on 31 August 2015</td></tr> <tr><td>vii)</td><td>Options exercisable at \$0.015 (or such greater price as determined by the Company at its discretion) on or before 15 October 2016. The Options will vest on 31 August 2016</td></tr> <tr><td>viii)</td><td>Performance Rights vesting over two years upon attainment of certain share price related hurdles.  No Performance Rights will vest if the share price does not exceed \$0.01, with 50% vesting if the share price is equal to or greater than \$0.01 and 100% vesting if the share price is equal to or greater than \$0.014, with pro rata adjustment for a share price between \$0.01 and \$0.014. 50% of the Performance Rights will be measured on 31 July 2015, with the balance being measured against the share price hurdles on 31 July 2016</td></tr> </table>	i)	Fully paid ordinary Shares	ii)	Options exercisable at \$0.015 on or before 30 September 2016	iii)	Fully paid ordinary Shares	iv)	Options exercisable at \$0.015 on or before 30 September 2016	v)	Options exercisable at \$0.015 on or before 30 September 2016	vi)	Options exercisable at \$0.015 (or such greater price as determined by the Company at its discretion) on or before 15 October 2016. The Options will vest on 31 August 2015	vii)	Options exercisable at \$0.015 (or such greater price as determined by the Company at its discretion) on or before 15 October 2016. The Options will vest on 31 August 2016	viii)	Performance Rights vesting over two years upon attainment of certain share price related hurdles.  No Performance Rights will vest if the share price does not exceed \$0.01, with 50% vesting if the share price is equal to or greater than \$0.01 and 100% vesting if the share price is equal to or greater than \$0.014, with pro rata adjustment for a share price between \$0.01 and \$0.014. 50% of the Performance Rights will be measured on 31 July 2015, with the balance being measured against the share price hurdles on 31 July 2016
i)	Fully paid ordinary Shares																
ii)	Options exercisable at \$0.015 on or before 30 September 2016																
iii)	Fully paid ordinary Shares																
iv)	Options exercisable at \$0.015 on or before 30 September 2016																
v)	Options exercisable at \$0.015 on or before 30 September 2016																
vi)	Options exercisable at \$0.015 (or such greater price as determined by the Company at its discretion) on or before 15 October 2016. The Options will vest on 31 August 2015																
vii)	Options exercisable at \$0.015 (or such greater price as determined by the Company at its discretion) on or before 15 October 2016. The Options will vest on 31 August 2016																
viii)	Performance Rights vesting over two years upon attainment of certain share price related hurdles.  No Performance Rights will vest if the share price does not exceed \$0.01, with 50% vesting if the share price is equal to or greater than \$0.01 and 100% vesting if the share price is equal to or greater than \$0.014, with pro rata adjustment for a share price between \$0.01 and \$0.014. 50% of the Performance Rights will be measured on 31 July 2015, with the balance being measured against the share price hurdles on 31 July 2016																
<p>4 Do the <sup>+</sup>securities rank equally in all respects from the <sup>+</sup>issue date with an existing <sup>+</sup>class of quoted <sup>+</sup>securities?</p> <p>If the additional <sup>+</sup>securities do not rank equally, please state:</p> <ul style="list-style-type: none"> <li>• the date from which they do</li> <li>• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>	<table border="1"> <tr><td>i)</td><td>Yes</td></tr> <tr><td>ii)</td><td>Not prior to exercise of Options</td></tr> <tr><td>iii)</td><td>Yes</td></tr> <tr><td>iv)</td><td>Not prior to exercise of Options</td></tr> <tr><td>v)</td><td>Not prior to exercise of Options</td></tr> <tr><td>vi)</td><td>Not prior to vesting date and exercise of Options</td></tr> <tr><td>vii)</td><td>Not prior to vesting date and exercise of Options</td></tr> <tr><td>viii)</td><td>Not prior to satisfaction of vesting conditions and conversion into ordinary Shares</td></tr> </table>	i)	Yes	ii)	Not prior to exercise of Options	iii)	Yes	iv)	Not prior to exercise of Options	v)	Not prior to exercise of Options	vi)	Not prior to vesting date and exercise of Options	vii)	Not prior to vesting date and exercise of Options	viii)	Not prior to satisfaction of vesting conditions and conversion into ordinary Shares
i)	Yes																
ii)	Not prior to exercise of Options																
iii)	Yes																
iv)	Not prior to exercise of Options																
v)	Not prior to exercise of Options																
vi)	Not prior to vesting date and exercise of Options																
vii)	Not prior to vesting date and exercise of Options																
viii)	Not prior to satisfaction of vesting conditions and conversion into ordinary Shares																

<sup>+</sup> See chapter 19 for defined terms.

5	Issue price or consideration	<ul style="list-style-type: none"> <li>i) \$0.005</li> <li>ii) Nil. Options to be issued on the basis of one Option for every two Shares subscribed for under the SPP Offer</li> <li>iii) \$0.005</li> <li>iv) Nil. Options to be issued on the basis of one Option for every two Shares subscribed for under the Placement</li> <li>v) Nil</li> <li>vi) Nil</li> <li>vii) Nil</li> <li>viii) Nil</li> </ul>
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	<ul style="list-style-type: none"> <li>i) Issue of Shares pursuant to SPP Offer</li> <li>ii) Issue of Options on the basis of one Option for every two Shares subscribed for under the SPP Offer</li> <li>iii) Issue of Shares pursuant to Placement</li> <li>iv) Issue of Options on the basis of one Option for every two Shares subscribed for under the Placement</li> <li>v) Issue of Adviser Placement Options as part consideration for corporate advisory services</li> <li>vi) Issue of incentive Class A Director Options</li> <li>vii) Issue of incentive Class B Director Options</li> <li>viii) Issue of Performance Rights as incentive to incoming Managing Director</li> </ul>
6a	Is the entity an <sup>+</sup> eligible entity that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h <i>in relation to the <sup>+</sup>securities the subject of this Appendix 3B</i> , and comply with section 6i	Yes
6b	The date the security holder resolution under rule 7.1A was passed	12 November 2013
6c	Number of <sup>+</sup> securities issued without security holder approval under rule 7.1	Nil

6d	Number of +securities issued with security holder approval under rule 7.1A	Nil														
6e	Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	<table><tr><td>i)</td><td>160,000,000</td></tr><tr><td>ii)</td><td>80,000,000</td></tr><tr><td>iii)</td><td>440,000,000</td></tr><tr><td>iv)</td><td>220,000,000</td></tr><tr><td>v)</td><td>20,000,000</td></tr><tr><td>vi)</td><td>6,000,000</td></tr><tr><td>vii)</td><td>6,000,000</td></tr></table> <p>Subject to shareholder approved on 1 September 2014</p>	i)	160,000,000	ii)	80,000,000	iii)	440,000,000	iv)	220,000,000	v)	20,000,000	vi)	6,000,000	vii)	6,000,000
i)	160,000,000															
ii)	80,000,000															
iii)	440,000,000															
iv)	220,000,000															
v)	20,000,000															
vi)	6,000,000															
vii)	6,000,000															
6f	Number of +securities issued under an exception in rule 7.2	viii) 30,000,000														
6g	If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.	N/A														
6h	If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A														
6i	Calculate the entity’s remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Refer to Annexure 1														
7	+Issue dates  Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.  Cross reference: item 33 of Appendix 3B.	On or around 5 September 2014														
8	Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)	<table><tr><th>Number</th><th>+Class</th></tr><tr><td>1,031,278,356</td><td>Ordinary Shares</td></tr><tr><td>320,000,000</td><td>Options exercisable at \$0.015 expiring 30 September 2016</td></tr></table>	Number	+Class	1,031,278,356	Ordinary Shares	320,000,000	Options exercisable at \$0.015 expiring 30 September 2016								
Number	+Class															
1,031,278,356	Ordinary Shares															
320,000,000	Options exercisable at \$0.015 expiring 30 September 2016															

<sup>+</sup> See chapter 19 for defined terms.

	Number	+Class
9	Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)	6,000,000
		Class A Director Options vesting on 31 August 2015 and expiring 15 October 2016
		6,000,000
		Class B Director Options vesting on 31 August 2016 and expiring 15 October 2016
		15,000,000
		Options exercisable at \$0.01 expiring 30 April 2017
		30,000,000
		Performance Rights expiring 31 July 2016
		1,000,000
		Performance Rights expiring 6 May 2015
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	N/A

## Part 2 - Pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the +securities will be offered	N/A
14	+Class of +securities to which the offer relates	N/A
15	+Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A

18	Names of countries in which the entity has security holders who will not be sent new offer documents  Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	N/A
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of	N/A

---

+ See chapter 19 for defined terms.

	their entitlements through a broker and accept for the balance?	<div></div>
32	How do security holders dispose of their entitlements (except by sale through a broker)?	<div>N/A</div>
33	+Issue date	<div>N/A</div>

## Part 3 - Quotation of securities

*You need only complete this section if you are applying for quotation of securities*

34 Type of +securities  
(tick one)

(a) ☒ +Securities described in Part 1

(b) ☐ All other +securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

### Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

*Tick to indicate you are providing the information or documents*

35	<input checked="" type="checkbox"/>	If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders
36	<input checked="" type="checkbox"/>	If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over
37	<input type="checkbox"/>	A copy of any trust deed for the additional +securities

## Entities that have ticked box 34(b)

38	Number of <sup>+</sup> securities for which <sup>+</sup> quotation is sought	N/A	
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought	N/A	
40	<p>Do the <sup>+</sup>securities rank equally in all respects from the <sup>+</sup>issue date with an existing <sup>+</sup>class of quoted <sup>+</sup>securities?</p> <p>If the additional <sup>+</sup>securities do not rank equally, please state:</p> <ul style="list-style-type: none"> <li>the date from which they do</li> <li>the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>	N/A	
41	<p>Reason for request for quotation now</p> <p>Example: In the case of restricted securities, end of restriction period</p> <p>(if issued upon conversion of another <sup>+</sup>security, clearly identify that other <sup>+</sup>security)</p>	N/A	
42	Number and <sup>+</sup> class of all <sup>+</sup> securities quoted on ASX (including the <sup>+</sup> securities in clause 38)	Number	<sup>+</sup> Class

<sup>+</sup> See chapter 19 for defined terms.



## Quotation agreement

- 1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted +quotation.
  - An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty
  - Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
  - If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- 4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: ..... Date: 8 August 2014  
(Company secretary)

Print name: Nicholas Ong

== == == == ==

---

+ See chapter 19 for defined terms.

# Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

### Part 1

Rule 7.1 – Issues exceeding 15% of capital	
<b>Step 1: Calculate “A”, the base figure from which the placement capacity is calculated</b>	
<b>Insert</b> number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	431,278,356
<b>Add</b> the following: <ul style="list-style-type: none"> <li>Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval</li> <li>Number of partly paid +ordinary securities that became fully paid in that 12 month period</li> </ul> <b>Note:</b> <ul style="list-style-type: none"> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	Nil  600,000,000  N/A
<b>Subtract</b> the number of fully paid +ordinary securities cancelled during that 12 month period	Nil
<b>“A”</b>	1,031,278,356

+ See chapter 19 for defined terms.

<b>Step 2: Calculate 15% of “A”</b>	
<b>“B”</b>	0.15 <i>[Note: this value cannot be changed]</i>
<b>Multiply “A” by 0.15</b>	154,691,753
<b>Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used</b>	
<b>Insert</b> number of +equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued: <ul style="list-style-type: none"> <li>Under an exception in rule 7.2</li> <li>Under rule 7.1A</li> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul> <b>Note:</b> <ul style="list-style-type: none"> <li><i>This applies to equity securities, unless specifically excluded – not just ordinary securities</i></li> <li><i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i></li> <li><i>It may be useful to set out issues of securities on different dates as separate line items</i></li> </ul>	Nil
<b>“C”</b>	Nil
<b>Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1</b>	
<b>“A” x 0.15</b> <i>Note: number must be same as shown in Step 2</i>	154,691,753
<b>Subtract “C”</b> <i>Note: number must be same as shown in Step 3</i>	Nil
<b>Total [“A” x 0.15] – “C”</b>	154,691,753 <i>[Note: this is the remaining placement capacity under rule 7.1]</i>

+ See chapter 19 for defined terms.

## Part 2

<b>Rule 7.1A – Additional placement capacity for eligible entities</b>	
<b>Step 1: Calculate “A”, the base figure from which the placement capacity is calculated</b>	
<b>“A”</b> <i>Note: number must be same as shown in Step 1 of Part 1</i>	1,031,278,356
<b>Step 2: Calculate 10% of “A”</b>	
<b>“D”</b>	0.10 <i>Note: this value cannot be changed</i>
<b>Multiply “A” by 0.10</b>	103,127,835
<b>Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used</b>	
<b>Insert</b> number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A  <i>Notes:</i> <ul style="list-style-type: none"> <li>• This applies to equity securities – not just ordinary securities</li> <li>• Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>• Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>• It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	Nil
<b>“E”</b>	103,127,835

+ See chapter 19 for defined terms.

<b>Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A</b>	
<b>“A” x 0.10</b> <i>Note: number must be same as shown in Step 2</i>	103,127,835
<b>Subtract “E”</b> <i>Note: number must be same as shown in Step 3</i>	Nil
<b>Total [“A” x 0.10] – “E”</b>	103,127,835 <i>Note: this is the remaining placement capacity under rule 7.1A</i>

---

+ See chapter 19 for defined terms.